Page last updated: 2024-11-08

k-strophanthin-beta

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

K-strophanthin-beta: contains beta-glucose, cymarose & strophanthidin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

strophanthin K: induces arrhythmias; see also K-strophanthin-beta [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID220861
MeSH IDM0069016
PubMed CID20055294
CHEMBL ID540506
CHEBI ID80753
SCHEMBL ID6940151
MeSH IDM0069016

Synonyms (42)

Synonym
strophanthidin-glucocymarosid
nsc-7670
560-53-2
strophanthin-k, beta
5.beta.-card-20(22)-enolide,6-dideoxy-4-o-.beta.-d-glucopyranosyl-3-o-methyl-.beta.-d-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-19-oxo-
k-strophanthin-.beta.
card-20(22)-enolide,6-dideoxy-4-o-.beta.-d-glucopyranosyl-3-o-methyl-.beta.-d-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-19-oxo-, (3.beta.,5.beta.)-
nsc7670
.beta.-k-strophanthin
nsc4320 ,
strophanthin k (crystalline)
strophanthin
.beta.-strophanthobioside, strophanthidin-3
NCI60_004001
nsc 4320
k-strophanthin-beta
FHIREUBIEIPPMC-UHFFFAOYSA-N
5.beta.-card-20(22)-enolide, 3.beta.-((2,6-dideoxy-4-o-.beta.-d-glucopyranosyl-3-o-methyl-.beta.-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-
card-20(22)-enolide, 3-[(2,6-dideoxy-4-o-.beta.-d-glucopyranosyl-3-o-methyl-.beta.-d-ribo-hexopyranosyl)oxy]-5,14-dihydroxy-19-oxo-, (3.beta.,5.beta.)-
3-[(2,6-dideoxy-4-o-hexopyranosyl-3-o-methylhexopyranosyl)oxy]-5,14-dihydroxy-19-oxocard-20(22)-enolide #
k935s3t1oe ,
unii-k935s3t1oe
5-18-05-00132 (beilstein handbook reference)
strophosid
strophanthin k
nsc-4320
strophanthidin-glucocymarosid [german]
(3beta,5beta)-3-((2,6-dideoxy-4-o-beta-d -glucopyranosyl-3-o-methyl-beta-d -ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxocard-20(22)-enolide
einecs 209-210-9
beta-strophanthobioside, strophanthidin-3
k-strophanthin-beta; card-20(22)-enolide, 3-((2,6-dideoxy-4-o-beta-d-glucopyranosyl-3-o-methyl-beta-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-, (3beta,5beta)-
brn 0076510
5-beta-card-20(22)-enolide, 3-beta-((2,6-dideoxy-4-o-beta-d-glucopyranosyl-3-o-methyl-beta-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-
beta-k-strophanthin
chebi:80753 ,
CHEMBL540506
SCHEMBL6940151
card-20(22)-enolide, 3-((2,6-dideoxy-4-o-.beta.-d-glucopyranosyl-3-o-methyl-.beta.-d-ribo-hexopyranosyl)oxy)-5,14-dihydroxy-19-oxo-, (3.beta.,5.beta.)-
k-strophanthin-beta (strophanthidin-cym-glc)
Q27149806
(3s,5s,8r,9s,10s,13r,14s,17r)-5,14-dihydroxy-3-[(2r,4s,5r,6r)-4-methoxy-6-methyl-5-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]p
DTXSID00971387

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Two parameters of "attenuation kinetics" are proposed to identify the pharmacodynamics and toxic kinetics on retina as time profile is concerned: 1) B (the slope of attenuation curve); 2) Et1/2 (half attenuative time)."( Retinal toxicity in albino rabbits induced by intravitreal injection of strophanthin-K.
Gu, PK; Jin, ZJ; Zeng, YC, 1990
)
0.28
" A threshold to the toxic arrhythmogenic effect of strophanthin K was significantly reduced as compared to that in the control group."( [Tolerance to cardiotoxic effect of strophanthane K in experimental total heart block and electrocardiostimulation].
Iskenderov, BG,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" A phenomenon of the dependence of a- and b-wave amplitude changes on dosage was demonstrated."( Retinal toxicity in albino rabbits induced by intravitreal injection of strophanthin-K.
Gu, PK; Jin, ZJ; Zeng, YC, 1990
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
cardenolide glycosideAny member of the class of cardenolides with glycosyl residues attached to position 3.
steroid aldehydeAny steroid substituted by a formyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID421971Growth inhibition of human U251 cells stably transfected with pGL3 plasmid after 24 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID421969Inhibition of HIF1 activation in human U251 cells stably transfected in pGL3 plasmid under hypoxic condition after 16 to 24 hrs by luciferase reporter gene assay2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
AID421970Growth inhibition of human U251 cells stably transfected with pGL2-TK-HRE plasmid after 24 hrs2009Journal of natural products, May-22, Volume: 72, Issue:5
Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (105)

TimeframeStudies, This Drug (%)All Drugs %
pre-199079 (75.24)18.7374
1990's17 (16.19)18.2507
2000's8 (7.62)29.6817
2010's1 (0.95)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1 (0.78%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies2 (1.56%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other125 (97.66%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]